MGMT and glioblastoma: In GBM studies such as ours, patients can be included at an advanced stage of disease or have altered general state of health, which means that their immediate survival may no longer depend on underlying molecular mechanisms, for example, MGMT methylation status, but rather on other prognostic factors such as age, WHO performance status, co‐morbidities or surgical management.